November 21, 2023
NOTICE CONVENING THE EXTRAORDINARY GENERAL MEETING IN ISOFOL MEDICAL AB (PUBL) 4 JANUARY 2024
November 10, 2023
ISOFOL PUBLISHES IT´S INTERIM REPORT
FOR THE PERIOD JANUARY-SEPTEMBER 2023
July 4, 2023
ISOFOL PRESENTS CONCLUSIONS FROM
THE IN-DEPTH ANALYSIS OF THE AGENT STUDY
This website is intended for use by residents of Sweden only
About Isofol
Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
Upcoming Events
- January 04, 2024 - January 04, 2024
Extraordinary General Meeting in Isofol Medical AB (publ) 4 January 2024 - February 20, 2024 - February 20, 2024
Year-end report 2023 - May 08, 2024 - May 08, 2024
Interim report January-March 2024
Media – Lates pressreleases
Isofol has received the first results from laboratory tests of arfolitixorin
GOTHENBURG, Sweden, December 7, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company has received the first results from…
Isofol is liquidating a subsidiary
GOTHENBURG, Sweden, December 1, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the subsidiary Isofol Medical (Incentive) AB, which has…
Notice convening the Extraordinary General Meeting in Isofol Medical AB (publ) 4 January 2024
GOTHENBURG, Sweden, November 21, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No….
INVESTORS – Latest reports and presentations
FOLLOW US
Stay updated on the latest news by
following Isofol on Linkedin.
